MedTrace Logo

Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)

NCT02480608 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2015-06-24

No results posted yet for this study

Summary

The study will test the tolerability and efficacy of the combination therapy Imatinib/Hydroxyurea (HU) in patients with chronic myeloid leukemia (CML) in first chronic phase (CP1) newly diagnosted or failing interferon-based therapy.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG

Imatinib

DRUG

Hydroxyurea

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2011-08-31
Completion
2013-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02480608 on ClinicalTrials.gov